Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of June 28th – July 4th, 2021.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view the full article.
Purchase Order From Red Light’s Wholly-Owned Distribution Company SR Wholesale for Creso’s CannaQIX® CBD Lozenges and CannaQIX® Hemp Instant Tea is Valued at CHF152,220 (A$218,803i) and Adds to Creso’s Growing Revenue Profile
Creso Pharma (ASX: CPH) (OTC: COPHF) (FRA: 1X8) announced that it has secured its first purchase order from Red Light Holland’s (CSE: TRIP) (OTC: TRUFF) (FRA: 4YX) wholly-owned distribution company SR Wholesale B.V. for Creso’s leading range of Swiss manufactured hemp CBD products. This marks the first purchase order between Red Light Holland and Creso Pharma and an important step ahead of the creation of The HighBrid Lab. Both parties are also aggressively pursuing product development initiatives to explore the potential of combining functional mushrooms and other compounds with Creso Pharma’s existing product suite, should the proposed merger with Red Light Holland be approved by shareholders.
Based in London, Curaleaf Said Tuesday the First Treatment Will Be Launched in Germany in the Months to Come
As Curaleaf’s (CSE: CURA) (OTCQX: CURLF) International subsidiary Adven GmbH seeks to advance its medical cannabis products in Germany, it has teamed up with an Italian pharmaceutical company, Zambon Spa, with whom it will provide medical cannabis treatments for patients, with an initial focus on neurological therapies.
Psilocybin-Assisted Therapy is a Rapidly Growing and Evolving Area of Interest for Medical Professionals, Clinicians and Patients With Multiple Mental Health Conditions Including Depression
Braxia Scientific (CSE: BRAX) (OTCQB: SHRMF) (FRA: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, announced it has launched its psilocybin-assisted clinical therapy training program. Through this program, Braxia will develop, train and support a new generation of qualified, skilled in best practices independent medical physicians, psychologists and psychotherapists to implement safe and effective psilocybin-assisted therapy for patients with depression. The therapists will participate in the provision of psychotherapy in upcoming clinical trials at Braxia evaluating the safety and efficacy of psilocybin in depression. The Company anticipates that, pending regulatory approval of psilocybin, therapists would also be trained to implement psychedelics in clinical practice.
Detroit-Headquartered Gage Growth, Currently Operates Nine Dispensaries Across the State of Michigan, Has Three Owned Cultivation Facilities and Agreements with Six Growers to Cultivate Their Proprietary Cannabis Strains
New pubco Gage Growth (CSE: GAGE) received lots of praise from PI Financial analyst Jason Zandberg in a coverage initiation on Wednesday. Zandberg said Gage’s focus on the hot Michigan cannabis market along with its quality retail network and exclusive brand partnerships are all pluses for this attractive single-state U.S. cannabis operator.
The Annual Russell Indexes Reconstitution Process Captures the 4,000 Largest U.S. Stocks in May of Every Year, Ranking Them By Total Market Capitalization
MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ) announced that effective Friday, June 25th, 2021, it has been added to the FTSE Russell 3000® index which measures the performance of the largest 3,000 U.S. companies. Robert Barrow, Chief Executive Officer of MindMed said, “Being included in mature and credible indexes like the FTSE Russell 3000® is a true honor. As we continue building MindMed and continue to achieve our important capital market and development milestones, our entire team remains dedicated and motivated to deliver on the potential positive change we can bring to the treatment of mental health and addiction in the years ahead.”
Reddit Users Have Been High on Tilray in Recent Months and Their Enthusiasm Has Been Warranted Based on the Canadian Cannabis Producer’s Stock Performance
Tilray’s (NASDAQ: TLRY) (FRA: 2HQ) shares have skyrocketed more than 160% year to date. But even the staunchest Tilray fans on Reddit could be thinking the same thing that Janet Jackson sang in the ’80s: “What have you done for me lately?” Over the last three months, the marijuana stock is down 10%. Sure, Tilray could stage a mighty comeback. However, here are three better stocks to buy than Tilray for investors seeking to profit from the cannabis boom: Ayr Strategies (CSE: AYR.A) (OTCQX: AYRSF), Cresco Labs (CSE: CL) (OTCQX: CRLBF) and Trulieve (CSE: TRUL) (OTCQX: TCNNF).
Numinus Was Also Recently Granted Tier 1 Issuer Status on the TSX Venture Exchange and the Company’s CEO Said He’s Hopeful That the Company Will Receive its Own Investment Bank Coverage in the Near Future
As more companies enter the space and go public, including Atai Life Sciences, which recently listed on the NASDAQ, the CEO said such moves “continue to broaden out the legitimacy of the industry.” “There is a massive opportunity to make a huge societal shift in a time where we recognize that it’s needed more than ever,” said Nyquvest.
Out of 15 Analysts Covering Trulieve’s Stock, Four Analysts Have Strong Buy Ratings and the Other 11 Have Buy Ratings
Over the last week, Trulieve (CSE: TRUL) (OTCQX: TCNNF) went on a virtual roadshow mainly focused on talking to international investors featured by Canaccord Genuity. Derek Dley, their analyst, says, “We came away from the investor meetings with increasing confidence in the company’s ability to develop market-leading positions in recently entered states, and through leveraging its pending acquisition of Harvest Health and Recreation.” He reiterated their C$97 12-month price target and speculative buy rating.
What Red Light CEO Todd Shapiro Loves About the Deal to Merge With Creso Pharma and Form the New Entity The HighBrid Lab
We chatted with Bruce Linton when Creso Pharma (ASX: CPH) (OTC: COPHF) (FRA: 1X8) and Red Light Holland’s (CSE: TRIP) (OTC: TRUFF) (FRA: 4YX) announced their plans to create a single global psychedelics and cannabinoid company called The HighBrid Lab. Today, we’re pleased to welcome Red Light Holland CEO Todd Shapiro to our table to discuss their end of the deal with HighBrid and what investors should be getting excited about.
These Top Marijuana Stocks Could Be Some of the Best Plays in Cannabis
Currently, many investors are asking themselves, is there still an opportunity to invest in top marijuana stocks in 2021? As it stands the cannabis sector has seen months of declines until it began to turn around in June. Now as we start July the US cannabis market is currently the center of attention and it seems most of the world is waiting for federal cannabis reform in 2021. With that said, analysts Trulieve (CSE: TRUL) (OTCQX: TCNNF) and Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2) are the top Marijuana Stocks to watch in 2021.
As a leading creator and publisher of original digital financial media, Wealthy VC features a series of industry-focused Investment articles dedicated to showing everyday Investors new opportunities in rapidly growing, little-known stocks in the stock market’s hottest sectors.
- This Company’s Hydrogen at the Pump Technology is Set to Make it the Tesla of Commercial Transportation
- These Clean Tech Stocks Will Clean Up With Biden’s New Spending Bill
- Four CleanTech Leaders Reddit May Take For a Ride